Association of Hysteroscopic vs Laparoscopic Sterilization With Procedural, Gynecological, and Medical Outcomes

Bouillon, Kim; Bertrand, Marion; Bader, G.; Lucot, Jean-Philippe; Dray‐Spira, Rosemary; Zureik, Mahmoud

doi:10.1001/jama.2017.21269

Cited by 45 publications

(53 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the large amount of individual data, regarding medications, inpatient diagnoses, medical, and laboratory procedures, allows inferring several comorbidities. This method is commonly applied in pharmacoepidemiological studies [35,36]. Similarly, the indication for treatment is not recorded in the databases, and available information has been compiled to define the clinical context of PPI prescription, used as a proxy of the indication.…”

Section: Discussionmentioning

confidence: 99%

Use of proton pump inhibitors in adults in France: a nationwide drug utilization study

Lassalle

Tri

Bardou

et al. 2019

Eur J Clin Pharmacol

Self Cite

View full text Add to dashboard Cite

Purpose Proton pump inhibitor (PPI) drugs are approved for the management of gastric acid-related diseases, mainly treatment of gastroesophageal reflux disease, treatment of nonsteroidal anti-inflammatory drugs (NSAID)-related gastrointestinal complications and prevention in at-risk patients, Helicobacter pylori eradication, and treatment of ulcers. PPIs are one of the most commonly prescribed drug class worldwide, and off-label use is widespread. The aim of this study was to describe outpatient PPI use of the whole adult population in France, based on the French National Health Data System (SNDS). Methods All individuals aged 18 years or older, with at least one dispensing for PPI between January 1, 2015 and December 31, 2015, were identified as PPI users. PPI users were considered as new users if they received no dispensing for PPI in the prior year. New users were followed until treatment discontinuation or up to 1 year, whichever occurred first. Characteristics of new users and of their PPI treatment were described, overall and separately by treatment indication. Results In total, 15,388,419 PPI users were identified in 2015 (57.0% women; mean age 57.0 years), accounting for 29.8% of the French adult population. Of them, 7,399,303 were new PPI users; mean treatment duration was 40.9 days, and 4.1% received a continuous PPI therapy lasting more than 6 months (10.2% among new users > 65 years versus 2.4% among those 18-65 years). For 53.5% of new users, indication for PPI therapy was a co-prescription with NSAID; in this indication, the large majority of patients (79.7%) had no measurable risk factor supporting a systematic prophylactic co-prescription of PPI. A proportion of 32.4% of new users did not have any identified comedication or inpatient diagnosis supporting an indication for PPI therapy; among them, only a small proportion (7.3% overall, and 8.4% of patients aged > 65 years) underwent a procedure investigating the digestive tract at the time of PPI initiation. Conclusion The results of this study suggest PPI overuse in France, not always in line with the French guidelines. In particular, inappropriate co-prescription with NSAID was frequent. Efforts should be made to limit PPI treatment to appropriate indications and durations.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of proton pump inhibitors in adults in France: a nationwide drug utilization study

Lassalle

Tri

Bardou

et al. 2019

Eur J Clin Pharmacol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Using a unique anonymous identifier, information from the SNIIRAM is linked to the French national hospital discharge database, which provides individual medical information on all hospital admissions in France, including discharge diagnoses (International Classification of Diseases, 10th edition (ICD-10)) and medical procedures performed. These databases have been used previously for large pharmacoepidemiological studies 10–13. Detailed individual-level information regarding hospitalisations and medical treatment was available from 1 January 2006 to 31 December 2014 and from 1 January 2010 to 31 December 2014, respectively.…”

Section: Methodsmentioning

confidence: 99%

Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study

Kirchgesner

Andersen

Carrat

et al. 2019

Gut

View full text Add to dashboard Cite

ObjectivePatients with IBD are at increased risk of acute arterial events. Antitumour necrosis factor (TNF) agents and thiopurines may, via their anti-inflammatory properties, lower the risk of acute arterial events. The aim of this study was to assess the impact of thiopurines and anti-TNFs on the risk of acute arterial events in patients with IBD.DesignPatients aged 18 years or older and affiliated to the French national health insurance with a diagnosis of IBD were followed up from 1 April 2010 until 31 December 2014. The risks of acute arterial events (including ischaemic heart disease, cerebrovascular disease and peripheral artery disease) were compared between thiopurines and anti-TNFs exposed and unexposed patients with marginal structural Cox proportional hazard models adjusting for baseline and time-varying demographics, medications, traditional cardiovascular risk factors, comorbidities and IBD disease activity.ResultsAmong 177 827 patients with IBD (96 111 (54%) women, mean age at cohort entry 46.2 years (SD 16.3), 90 205 (50.7%) with Crohn’s disease (CD)), 4145 incident acute arterial events occurred (incidence rates: 5.4 per 1000 person-years). Compared with unexposed patients, exposure to anti-TNFs (HR 0.79, 95% CI 0.66 to 0.95), but not to thiopurines (HR 0.93, 95% CI 0.82 to 1.05), was associated with a decreased risk of acute arterial events. The magnitude in risk reduction was highest in men with CD exposed to anti-TNFs (HR 0.54, 95% CI 0.40 to 0.72).ConclusionExposure to anti-TNFs is associated with a decreased risk of acute arterial events in patients with IBD, particularly in men with CD.

show abstract

“…Numerous international scientific publications and epidemiologic studies have used these databases. 11 , 12 , 13 , 14 , 15 …”

Section: Methodsmentioning

confidence: 99%

Evaluation of the Incidence of Hematologic Malignant Neoplasms Among Breast Cancer Survivors in France

et al. 2019

Self Cite

View full text Add to dashboard Cite

Key Points Question Which hematologic malignant neoplasm types are more prone to develop after breast cancer diagnosis? Findings In this cohort study of 439 704 French women, breast cancer survivors with an incident breast cancer diagnosis had statistically significantly higher standardized incidence rate ratios of acute myeloid leukemia and myelodysplastic syndrome compared with women in the general population. A slight increase in the incidence of multiple myeloma and acute lymphoblastic leukemia was noted. Meaning This study sugests that acute myeloid leukemia, myelodysplastic syndrome, and acute lymphoblastic leukemia occur more frequently among breast cancer survivors than among women in the general population; continuous monitoring and further investigations into the underlying mechanisms of hematologic malignant neoplasms are necessary.

show abstract

Association of Hysteroscopic vs Laparoscopic Sterilization With Procedural, Gynecological, and Medical Outcomes

Cited by 45 publications

References 37 publications

Use of proton pump inhibitors in adults in France: a nationwide drug utilization study

Use of proton pump inhibitors in adults in France: a nationwide drug utilization study

Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study

Evaluation of the Incidence of Hematologic Malignant Neoplasms Among Breast Cancer Survivors in France

Contact Info

Product

Resources

About